Annual Report

The report presents Kyowa Kirin's transformation into a Japan-based Global Specialty Pharmaceutical Company, supported by global strategic products and a new 2030 vision. It describes a structured materiality process spanning social and business perspectives, with priorities including diversity, occupational safety, climate change, water and waste. Environmental highlights include hydropower procurement at the Takasaki Plant and a net-zero CO2 ambition across the entire value chain by 2050. The report also details governance, human-resource initiatives and global risk-management systems.

Report type

Integrated Report

Class

Embedded

Scope

Full report

Fiscal year

2020

Period

1 January 2020 – 31 December 2020

Language

English

Pages

 

File size

 

Restatement

Disclosed

GRI

••••••

SASB

••••••

TCFD

••••••

ISSB

••••••

ESRS

••••••

Integrated Reporting Framework

••••••

GHG Protocol

••••••

EU Taxonomy

••••••

CDP

••••••

Other

••••••

CDP score

••••••

Assessment

••••••

Basis

••••••

Statement included

••••••